Two more recent trials of CD combined with artesunate (CDA), in areas where G6PD deficiency is more common, have clearly shown that there is a substantially increased risk of severe anaemia with CD for G6PD A- patients [8], [9] and for this reason CD was withdrawn and the development of CDA was not taken further [2], [35]. The gene discussed is G6PD; the disease is G6PD deficiency.